Weight: Under 11 pounds (mini), 16–32 pounds (standard) ...

BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales ...

UK MHRA grants marketing approval for BridgeBio Pharma’s Beyonttra to treat ATTR-CM: Palo Alto, California Wednesday, April 30, 2025, 16:00 Hrs [IST] BridgeBio Pharma, Inc., a n ...

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch ...

And many people with the condition are cared for at home.

Metabolic syndrome is associated with increased risk for early-onset all-cause dementia, Alzheimer’s disease, and vascular ...

Commercial Progress: The first full quarter of Attruby net product revenue was $36.7 million. As of April 25, 2025, 2,072 unique patient prescriptions for Attruby have been written by 756 unique ...

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

An increase in physical activity between the ages of 45 and 65 could help prevent Alzheimer's disease, while inactivity may be detrimental to brain health.

Scientists using living human brain tissue have shown for the first time how a toxic form of a protein linked to Alzheimer's ...